News
- Author:
- Zosia Chustecka
Publish date: August 6, 2020
The first-in-class drug belantamab mafodotin (Blenrep) has been approved in the United States for use in relapsed and refractory multiple myeloma.<...
News
- Author:
- Zosia Chustecka
Publish date: August 4, 2020
The humanized CD19-targeting monoclonal antibody mediates B-cell lysis through apoptosis and an immune effector m...
News
- Author:
- Zosia Chustecka
Publish date: June 16, 2020
Lurbinectedin is approved to treat adults with metastatic small-cell lung cancer with disease progression on or a...
News
- Author:
- Zosia Chustecka
Publish date: May 11, 2020
ASCO’s chief medical officer explains how this year’s virtual annual meeting will work.
News
- Author:
- Zosia Chustecka
Publish date: May 11, 2020
The FDA has approved selpercatinib (Retevmo) to treat lung and thyroid cancers with RET gene alterations.<...
News
- Author:
- Zosia Chustecka
Publish date: April 20, 2020
The FDA approved pemigatinib to treat adults with previously treated, unresectable, locally advanced or metastati...
News
- Author:
- Zosia Chustecka
Publish date: April 14, 2020
Data are ‘almost uninterpretable,’ says one drug researcher.
News
- Author:
- Zosia Chustecka
Publish date: March 11, 2020
AACR, SGO, NCCN, and other meetings have been canceled or postponed because of the coronavirus outbreak.
News
- Author:
- Zosia Chustecka
Publish date: December 13, 2019
ORLANDO – The “practice-changing” study found that blinatumomab was less toxic and allowed more patients to proceed to transplant.
News
- Author:
- Zosia Chustecka
Publish date: December 13, 2019
ORLANDO – Mosunetuzumab is a bispecific antibody that targets both CD3 and CD20. It was tested in a phase 1/1b trial among patients with relapsed/r...
